Aescap 2.0 is organizing investor meetings in the month of November
At several dates in November we organize round table meetings for potential investors where our investment philosophy and methodology will be discussed in an interactive setting. Click here to see which dates you can attend.
Aescap invests in high-growth companies dedicated to develop and market highly innovative medical treatments. It typically invests in those comapnies that are de-risked from a technology and finance perspective.
Aescap’s latest fund, Aescap 2.0, has generated a net performance of 29.6% over the first 18 months since its start (at October 1 2017). The fund’s ability to outperform the market is the result of a focused investment strategy, investing in 15-20 biotech companies at a time. Another important pillar under our success is the multi-disciplinary set-up of our team, with most team members having been part of the healthcare industry for over 25 years.
Aescap 2.0 is now open to new investors, investors can join or exit the fund on a monthly basis. Please feel free to give us a call at +31 20 570 29 40 for more information or to receive a prospectus.